The Generic Oncology Sterile Injectable Market was valued at US$ 8.9 Billion in 2016 and is expected to exhibit a CAGR of 11.4% over the forecast period (2017–2025).

Generic oncology sterile injectables are used in treatment of various types of cancers such as ovarian, breast, and lung. These drugs are relatively cheaper than branded counterparts. This is owing presence of same active ingredients, although its inactive contents are different. Cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer drugs by 86% in March 2017. Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry is expected to fuel growth of the generic oncology sterile injectables during the forecast period. Also, the emergence of biosimilars has also impacted growth of generics drugs. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars had a major share in Europe since 2013 and in the U.S. since 2015 and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Market Dynamics

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancers were reported in the U.S. Manufacturers are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following U.S. Food and Drug administration approval in the U.S. market.  Clofarabine is a generic version of Genzyme's Clolar, which is used for treatment of refractory acute lymphoblastic leukemia for patients aged 1 year to 21 years.

Competitive Landscape

The key players in generic oncology sterile injectable market includes, Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/562

Generic oncology sterile injectables are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectables have to adhere to regulations by the Food and Drug Administration (FDA) for the process of development of these injectables, which are equivalent to that for branded counterparts. These generic oncology sterile injectables are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus.

These injectables are available at low prices, and therefore, are widely preferred over branded. Furthermore, R&D for generic drugs requires less capital, which increases competition to enter into generic oncology sterile injectable market as soon as the patent for branded injectables expires. However, the emergence of biosimilars has increased in past few years. After Europe, the number of biosimilars approved is increasing in the U.S. market. This is expected to contribute largely towards the generic oncology sterile injectable market growth during the forecast period.

Rising number of cancer cases is expected to fuel demand for treatment drugs and injectables. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases are expected to increase. This is expected to drive growth of the generic oncology sterile injectable market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]